Skip to main content

Month: June 2021

Diversified Royalty Corp. Announces June 2021 Cash Dividend and Annual General Meeting Details

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.01667 per common share for the period of June 1, 2021 to June 30, 2021, which is equal to $0.20 per common share on an annualized basis. The dividend will be paid on June 30, 2021 to shareholders of record as of the close of business on June 15, 2021. Annual General Meeting The Corporation will be holding its Annual General Meeting of shareholders at 9:00 am (Pacific time) on Monday, June 28, 2021 (the “Meeting”). In order to ensure the safety of our shareholders, colleagues, stakeholders and the community at large and to comply with physical distancing recommendations and mandates of public health authorities...

Continue reading

Class Acceleration Corp. Receives NYSE Notice Regarding Delayed Form 10-Q Filing

WOODSIDE, Calif., June 03, 2021 (GLOBE NEWSWIRE) — Class Acceleration Corp. (NYSE: CLAS, CLAS.U, CLAS.W) (the “Company”) today announced that it received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The notice has no immediate effect on the listing of the Company’s stock on the NYSE. The NYSE informed the Company that, under the NYSE’s rules, the Company can regain compliance with the NYSE’s continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any...

Continue reading

Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders

BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021. Dr. Simon Pimstone, Executive Chair of Xenon’s Board of Directors stated, “We announced plans for a leadership transition earlier in the year, implemented a seamless succession plan, and effected these appointments at our Annual Meeting. Ian Mortimer, who takes on the role of CEO and joins our board of directors, has worked alongside me for the past seven years and is ideally suited to lead Xenon, together with Sherry Aulin, who was appointed Xenon’s Chief Financial Officer. It has been a privilege to head up this talented executive team while serving Xenon’s...

Continue reading

LGI Homes Reports May 2021 Home Closings

THE WOODLANDS, Texas, June 03, 2021 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 911 homes in May 2021, up from 640 homes closed in May 2020, representing year-over-year growth of 42.3%. The Company ended the first five months of 2021 with 4,420 home closings, a 43.5% increase over 3,080 home closings during the first five months of 2020. As of May 31, 2021, the Company had 104 active selling communities. About LGI Homes, Inc. Headquartered in The Woodlands, Texas, LGI Homes, Inc. engages in the design, construction and sale of homes in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia and Pennsylvania. Since 2018, LGI Homes has been ranked as the 10th largest...

Continue reading

INDUS Announces Updates to Acquisition and Disposition Pipelines

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) — INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) announced today that it recently entered into an agreement (the “Purchase Agreement”) to acquire, for a purchase price of $42.0 million, an approximately 50% leased, 395,000 square foot industrial/logistics building in Charlotte, North Carolina (the “Charlotte Acquisition”). Under the terms of the Purchase Agreement, INDUS expects to close on the Charlotte Acquisition by the end of the 2021 second quarter. Michael Gamzon, President and Chief Executive Officer of INDUS, commented, “We are very excited by this opportunity to expand our presence in the Charlotte market. This acquisition complements our existing portfolio and development pipeline and offers additional upside as we pursue leasing opportunities for the balance...

Continue reading

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – –  Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the toripalimab arm compared to placebo – – Data to be presented June 6, 2021 at ASCO plenary session – – Over 30 toripalimab abstracts in more than 10 tumor types published at ASCO 2021 – SHANGHAI, China, and REDWOOD CITY, Calif., June 03, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results from the pivotal study “JUPITER-02”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating...

Continue reading

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30, two-sided))1 No new safety signals emerged in long-term follow-up with median of 6.3 years; safety profile consistent with previously reported results1Previously reported primary analysis demonstrated statistically significant improvement in progression free survival2Novartis is committed to reimagining cancer through radioligand therapy with more than 15 dedicated research and discovery programs; recent investments and partnerships further strengthen platform capabilitiesBasel, June 3, 2021 — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide...

Continue reading

CareTrust REIT, Inc. Announces Pricing of $400 Million in Senior Notes due 2028

SAN CLEMENTE, Calif., June 03, 2021 (GLOBE NEWSWIRE) — CareTrust REIT, Inc. (Nasdaq: CTRE) (“CareTrust REIT”) announced today that its wholly owned subsidiaries CTR Partnership, L.P. and a corporate co-issuer, CareTrust Capital Corp. (together, the “Issuers”), priced their private offering of $400 million aggregate principal amount of senior unsecured notes due 2028 (the “Notes”). The Notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be senior unsecured obligations of the Issuers and will be jointly and severally guaranteed by CareTrust REIT and CareTrust REIT’s existing and future subsidiaries that guarantee...

Continue reading

iSIGN Media Announces the Close of its Previously Announced Private Placement of $400,000

TORONTO, June 03, 2021 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions, announced that it has closed its previously announced non-brokered private placement (“Placement”) for aggregate gross proceeds of $400,000. Under the terms of the Offering the Company will issue 8 million Units at a price of $0.05 per Unit. Each Unit consists of one Common Share of the Company (each a “Common Share” and collectively, the “Common Shares”) and one common share purchase warrant (each warrant referred to herein as a “Warrant” and collectively, the “Warrants”). Each Warrant will entitle the holder to purchase one Common Share at a price of $0.075 for a period of 24 months from the date of closing. All...

Continue reading

Stemming from SEC Guidance Concerning Accounting Treatment of Warrants, Kismet Acquisition Three Corp. Announces Receipt of Nasdaq Continued Listing Standard Notice

Moscow, Russia, June 03, 2021 (GLOBE NEWSWIRE) — Kismet Acquisition Three Corp. (the “Company”) today announced that on May 28, 2021 it received a deficiency letter from the Nasdaq Capital Market (“Nasdaq”) relating to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) as required under Section 5250(c) of the Nasdaq Rules and Regulations. On April 12, 2021, the staff of the Securities and Exchange Commission (“SEC”) issued “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “Statement”), which clarified guidance for all SPAC-related companies regarding the accounting and reporting for their warrants. The immediacy of the effective date of the new guidance set...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.